216 related articles for article (PubMed ID: 8769377)
1. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels.
Reubi JC; Schaer JC; Laissue JA; Waser B
Metabolism; 1996 Aug; 45(8 Suppl 1):39-41. PubMed ID: 8769377
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.
Reubi JC; Waser B; Schaer JC; Laissue JA
Eur J Nucl Med; 2001 Jul; 28(7):836-46. PubMed ID: 11504080
[TBL] [Abstract][Full Text] [Related]
4. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
Reubi JC; Schär JC; Waser B; Wenger S; Heppeler A; Schmitt JS; Mäcke HR
Eur J Nucl Med; 2000 Mar; 27(3):273-82. PubMed ID: 10774879
[TBL] [Abstract][Full Text] [Related]
5. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors.
Reubi JC; Schaer JC; Waser B; Hoeger C; Rivier J
Eur J Pharmacol; 1998 Mar; 345(1):103-10. PubMed ID: 9593601
[TBL] [Abstract][Full Text] [Related]
6. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
7. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.
Park S; Kamegai J; Johnson TA; Frohman LA; Kineman RD
Endocrinology; 2000 Oct; 141(10):3556-63. PubMed ID: 11014208
[TBL] [Abstract][Full Text] [Related]
8. 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo.
Visser-Wisselaar HA; Van Uffelen CJ; Van Koetsveld PM; Lichtenauer-Kaligis EG; Waaijers AM; Uitterlinden P; Mooy DM; Lamberts SW; Hofland LJ
Endocrinology; 1997 Mar; 138(3):1180-9. PubMed ID: 9048625
[TBL] [Abstract][Full Text] [Related]
9. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery.
Fehlmann D; Langenegger D; Schuepbach E; Siehler S; Feuerbach D; Hoyer D
J Physiol Paris; 2000; 94(3-4):265-81. PubMed ID: 11088004
[TBL] [Abstract][Full Text] [Related]
10. Drug design at peptide receptors: somatostatin receptor ligands.
Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
13. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
[TBL] [Abstract][Full Text] [Related]
14. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
15. A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas.
Körner M; Waser B; Christ E; Beck J; Reubi JC
Neuroendocrinology; 2018; 106(2):116-127. PubMed ID: 28384628
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
17. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptors in pituitary function, diagnosis and therapy.
Hofland LJ; Lamberts SW
Front Horm Res; 2004; 32():235-52. PubMed ID: 15281350
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
20. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
